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Although great progress has been made in the past decade toward understanding the 
pathogenesis of rheumatoid arthritis (RA), clinicians remain some distance from a goal 
of personalized health care. The capacity to diagnose RA early, predict prognosis, and 
moreover predict response to biologic therapies has been a research focus for many 
years. How currently available clinical prediction models can facilitate such goals is 
reviewed in this article. In addition, the role of current imaging techniques in this regard 
is also discussed. Finally, the authors review the current literature regarding synovial bio-
markers and consider whether integration of synovial pathobiology into clinical prediction 
algorithms may enhance their predictive value.
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iNTRODUCTiON
Rheumatoid arthritis (RA) is characterized by a chronic symmetrical synovitis and underlying 
erosion of the subchondral bone and cartilage. It is associated with significant morbidity and mortal-
ity, with erosive damage directly related to disability and an economic burden for the UK economy 
alone of around £4 billion. It is now well recognized that the early diagnosis and treatment of RA 
equates to better long-term outcomes (1). The use of biologic drugs has transformed the treatment 
of RA, and since infliximab first came into routine clinical practice in the late 1990s, the biologics 
market for RA has expanded to include more than nine licensed preparations, with significantly 
more in late stage clinical development. Generally such agents are well tolerated, but adverse events 
can be severe and fatal and added to this is a high financial cost, with an annual cost of £200 million in 
the UK alone. Although variable, clinical trial data suggest response rates of around 60% (2) with first 
biologic treatment, as assessed by the composite clinical assessment tool of the American College 
of Rheumatology (ACR) 20 response or a fall in disease activity score of 28 joint count (DAS28) 
of >1.2. However, such level of clinical response is of modest significance to patient functionality, 
while an ACR 70 response that would enable patients to work and look after their family is reached 
in only 20–25%. Thus, a large proportion of patients (approximately 80%) are left with no response 
or significant ongoing disease activity. Additionally, a further proportion of patients will develop 
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secondary failure following an initially promising response, 
leaving altogether a huge unmet medical need.
In the era of personalized health care, a major focus of rheu-
matological research has been on predicting prognosis of RA, 
focusing on three main areas: (i) the early diagnosis and treat-
ment of RA, (ii) predicting prognosis following diagnosis of RA, 
and (iii) predicting response to biologic therapies. On this basis, 
a number of clinical prediction models have been developed 
with variable reports of specificity and sensitivity for both early 
diagnosis and predicting prognosis of RA.
Synovial tissue is a crucial mediator of cartilage and subchon-
dral bone erosion in RA and as such remains at the epicenter 
of joint pathology, although its exact place in the hierarchy of 
disease initiation and/or perpetuation is not entirely clear. In 
particular, the transition from the pre-clinical phase [breach of 
tolerance in secondary lymphoid organs (SLOs), mucosal associ-
ated lymphoid tissues, e.g., gut (GALT) and bronchial (BALT)] 
to localizing the disease to the joint is not fully understood. 
However, once the disease gets hold of the joint, examination 
of pathobiological specimens from the target organ, similarly 
to many other branches of medicine, including nephrology, 
dermatology, gastroenterology, and oncology, may become part 
of standard clinical care, with management decisions directed by 
the integration of pathobiology into clinical prediction models. 
With the advent of new techniques, such as ultrasound-guided 
synovial biopsy (3), the acquisition of synovial tissue has become 
a simple and well-tolerated procedure and emulating such a diag-
nostic/prognostic oncological model a potential goal. It is in this 
context that this review will discuss the currently available clinical 
prediction models and address whether the future integration of 
synovial pathobiology may make personalized health care in RA 
a more tangible objective.
CURReNT CLiNiCAL PReDiCTiON 
MODeLS
Predictive Models for the Diagnosis of RA 
in early inflammatory Arthritis
The first clinical prediction model for use in early inflamma-
tory arthritis was that developed by Henk Visser et al. (4). In a 
study of 524 early arthritis patients, seven variables: (i) symp-
tom duration at first visit, (ii) early morning stiffness (EMS), 
(iii) arthritis in three or more joints, (iv) bilateral compression 
pain in the metatarsophalangeal (MTP) joints, (v) rheumatoid 
factor (RF) positivity, (vi) anti-citrullinated protein antibodies 
(ACPA) positivity, and (vii) the presence of erosions (hands/feet) 
were modeled for predictivity and shown to reliably discriminate 
between self- limiting, persistent non-erosive, and persistent 
erosive arthritis at 2-year follow-up. A subsequent model, again 
originating from the Leiden Early Arthritis Clinic (5), was devel-
oped for use in patients with early undifferentiated inflammatory 
arthritis to assess progression to erosive arthritis RA. The authors 
examined nine clinical variables: (i) sex, (ii) age, (iii) localization 
of symptoms, (iv) severity of EMS, (v) the tender joint count, 
(vi) the swollen joint count (SJC), (vii) C-reactive protein (CRP) 
level, and the presence of (viii) RF, or (ix) ACPA. These were 
modeled (6) into a 14-point scale in a cohort of 570 early arthritis 
patients. They demonstrated that the positive predictive value for 
the development of RA with a score of 8 or greater was 91% and 
that the negative predictive value for patients with a score of 6 or 
lower was 84% and, further, that virtually none of the patients 
with a score of 3 or less were ultimately diagnosed with RA. This 
prediction rule has been validated in a number of other patient 
cohorts (7, 8) with similarly encouraging results. It should be 
noted, however, that 25% of patients in the study had a score 
between 6 and 8 and for these patients the chance of developing 
RA or not was equal, indicating the need for improvement of 
available predictive models in a quarter of patients.
The recognition that the 1987 ACR classification criteria for 
RA were unable to reliably diagnose patients with early disease 
led to the development of the ACR/EULAR 2010 classification 
criteria for RA (9), a process that incorporated a data-driven 
approach with consensus opinion. The 2010 classification criteria 
weight the acute phase response [erythrocyte sedimentation rate 
(ESR)/CRP], joint involvement (number and size affected), dura-
tion of symptoms (>6  weeks), and seropositivity for RF/ACPA 
antibodies. These criteria (along with the van der Helm and Visser 
criteria) have most recently been explored in the REACH study 
cohort (10) with outcome measures defined as methotrexate use 
and persistent disease at 12 months. When comparing the ACR/
EULAR 2010 criteria with the van der Helm and Visser scores, a 
superior sensitivity (0.74 vs 0.1 vs 0.59), although lower specific-
ity (0.66 vs 1.0 vs 0.93) was demonstrated for the ACR/EULAR 
criteria (10). Currently, the individual criteria of the ACR/EULAR 
2010 criteria are being analyzed within other early arthritis cohorts 
with the aim of further improving its diagnostic value (11).
Predictive Models for the Prognosis of RA
Once RA is diagnosed, predicting the subsequent clinical course 
remains a challenge and in particular those patients at risk of rapid 
radiographic progression. Although a number of factors including 
seropositivity for RF/ACPA, baseline radiographic erosions, and 
high inflammatory markers associate with a higher erosive load 
(12–16), none are sufficient independent predictors of outcome 
(15). A number of clinical prediction models have, therefore, 
been developed in an attempt to overcome this difficulty (14, 17, 
18) with data in general demonstrating that combining factors 
improves predictive power. For example, a model combining 
ACPA, sex, ESR, and IgM RF, was reported to have an accuracy 
of 73.6% to predict radiographic progression (19). A more recent 
report has suggested that integrating easily accessible clinical and 
laboratory variables (28 SJC, RF, and CRP or ESR) into a visual 
matrix model enables identification of those patients at risk of 
rapid radiological progression (6). The same visual matrix model 
was subsequently validated in an early arthritis cohort by Durnez 
et  al. (20) to examine whether its application would improve 
therapeutic decision-making, but although it appeared to prevent 
overtreatment in the population studied, the predictive capacity 
for rapid radiological progression was low. Finally, this model (6) 
was also examined alongside two other prediction models, the 
BEST (21) and the SWEFOT model (19) in an observational RA 
cohort (22), and all three were found to have limited power to 
predict rapid radiological progression. More recently, a simplified 
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model incorporating three clinical parameters has been reported 
although sensitivity/specificity of prediction of radiographic 
damage was less with an AUC of 0.75 (23).
Finally, although not specifically a clinical model the widely 
validated multi-biomarker disease activity score, incorporating 
12 serum biomarkers has recently been demonstrated to reli-
ably predict radiographic progression at 12-month follow-up 
in a cohort of early RA patients although requires validation in 
further cohorts (24).
iNCORPORATiNG iMAGiNG iNTO 
CLiNiCAL PReDiCTiON MODeLS FOR 
THe DiAGNOSiS AND PROGNOSiS OF RA
Magnetic resonance imaging (MRI) and ultrasonography (US) 
have shown utility both in the early diagnosis of inflammatory 
arthritis and in monitoring its progression, and as such, a number 
of studies have examined their use as diagnostic/prognostic mark-
ers. MRI has been demonstrated to identify bone erosions early 
(25) and, furthermore, as a sensitive means to detect synovitis and 
bone marrow edema (26, 27). What is currently unclear, however, 
is how MRI functions as a tool to diagnose RA or further to 
predict its prognosis. Indeed a recent systematic review by Suter 
et al. (28) found no consensus on early MRI diagnostic criteria for 
RA and further concluded that bone marrow edema was the only 
significant predictor of radiographic progression (29). This is line 
with results from Duer-Jensen et al. (30) who examined predic-
tive MRI features in an early undifferentiated arthritis cohort and 
identified BME as an independent predictor of subsequent RA 
development. The authors went on to integrate BME into a clinical 
matrix prediction model and directly compared the performance 
with the previously described van der Helm-van Mihl model 
(vdHvM model) (5) and reported an enhanced performance 
in this cohort with the former model correctly identifying the 
development of RA in 82 vs 60.2% of patients. The importance of 
BME was also highlighted by Tamai et al., who demonstrated in 
an early arthritis cohort that the combination of BME and ACPA 
positivity was equivalent to the application of the vdHvM model 
(31). Furthermore, the demonstration in a RF-negative cohort 
of 40 early arthritis patients (32) that MRI features of synovitis, 
erosions, and BME were significantly more sensitive than ACPA 
in correctly identifying RA patients suggest a potentially valuable 
role for MRI in this particular cohort.
Magnetic resonance imaging continues to be an expensive 
imaging modality, however, and is also time consuming and cum-
bersome for the patient. Conversely US can be performed swiftly 
and relatively cheaply within outpatient clinics, a considerable 
advantage, particularly as immediate treatment decisions can then 
be made following the scan mostly carried out and interpreted 
by rheumatologists. Again, it has been shown to be a sensitive 
tool to identify early erosions and synovitis (33). An initial report 
by Freeston et  al. demonstrated a diagnostic benefit to adding 
ultrasonographic examination of the metacarpalphalangeal 
(MCP) joints, wrists, and flexor tendons to conventional clinical 
tools (RF/ACPA status, ESR/CRP, radiographic damage) for the 
diagnosis of very early inflammatory arthritis (34). The predictive 
algorithm appeared particularly helpful in seronegative patients, 
with a probability of certain diagnosis increasing from 30 to 94% 
once ultrasonographic features were incorporated. Interestingly, 
a recent study performed in very early arthritis incorporated US 
(of the MCP, wrist, and MTP joints) into both the van der Helm 
clinical prediction model and the ACR/EULAR 2010 classifica-
tion criteria and demonstrated that incorporating ultrasound 
increased sensitivity for both clinical prediction models (35). 
Conversely, however, data from a real-life early arthritis clinic 
(36) cohort of 379 patients did not demonstrate a benefit in the 
addition of US into a risk metric derived from 12 clinical and 
serological parameters for the prediction of the development of 
either persistent inflammatory arthritis or RA.
Clinical Predictive Models for Response  
to Biologic Treatment in RA
As already mentioned predicting the response to biologic agents 
is critical to the management of patients in order to optimize 
response and limit serious side effects. Although there are no 
clearly validated models for any of the biologic agents, a number 
of biomarkers have been explored. First, seropositivity for RF and 
ACPA and the primary response to anti-TNF agents has been 
examined in a number of cohorts (37–39) with mixed results, and 
thus at present, neither can be recommended as reliable biomark-
ers. Interestingly, however, it is becoming increasingly clear that 
seropositivity for RF and/or ACPA does enhance response to 
rituximab (40–42). Similarly, enhanced retention to abatacept in 
patients seropositive for RF and/or ACPA has also been observed 
in two independent cohorts (43, 44). Despite these observations, 
significant clinical challenges remain in predicting response to 
rituximab or abatacept with wide variability seen in response 
rates within the seropositive groups. Finally, preliminary data 
from an observational cohort of 530 RA patients have suggested 
that high levels of CRP retention with tocilizumab (45).
wHAT CAN SYNOviAL PATHOBiOLOGY 
ADD TO CURReNT CLiNiCAL 
PReDiCTiON MODeLS?
Thus, while clinical prediction models offer potential (sum-
marized in Table 1), they have a number of limitations, and at 
present, none are used in routine clinical practice, primarily 
because of lack of validation in large routine patient cohorts 
outside specialized centers and levels of sensitivity/specificity. 
These are important considerations and with a long-term goal of 
personalized health care much effort has gone into the search for 
additional biomarkers.
Rheumatoid arthritis is characterized by a thickened synovial 
membrane infiltrated by a diverse array of inflammatory cells, 
including macrophages, T and B lymphocytes, and NK  cells 
associated with the proliferation of resident synovial fibroblasts. 
One of the characteristics of rheumatoid synovial tissue is the 
frequent capacity of the inflammatory cell infiltrate to organize 
into aggregates, a process termed ectopic lymphoneogenesis 
(Figure  1). These aggregates are primarily composed of B and 
T lymphocytes, macrophages, and frequently follicular dendritic 
TABLe 1 | Summary of diagnostic clinical prediction models in rheumatoid arthritis.
Clinical 
prediction model
variables Target 
population
Outcome Sensitivity/
specificity
validated on 
external cohorts 
yes/no
Visser et al. (4) i. Symptom duration, ii. early morning stiffness (EMS),  
iii. arthritis in >3 joints, iv. +ve metatarsophalangeal  
compression test, v. RF+ve, vi. ACPA+ve, vii. presence of erosions
Inflammatory 
arthritis
Self limiting vs 
persistent non-
erosive (PNE), 
persistent erosive 
(PE) at 2-year 
follow-up
AUC 0.84 SI 
vs PE
Yes, e.g., Ref. (10)
AUC 0.91 PNE 
vs PE (4)
Van der Helm-van 
Mil et al. (5)
i. Sex, ii. age, iii. localization of symptoms, iv. severity of  
EMS, v. tender joint count, vi. swollen joint count, vii. C-reactive 
protein, viii. RF+/− or ix. ACPA+/−
Undifferentiated 
arthritis
Erosive disease AUC 0.87 (5) Yes, e.g., Ref. 
(7, 10)
ACR/EULAR 2010 
criteria, Aletaha 
et al. (9)
i. ESR/CRP, ii. joint involvement (number and size affected),  
iii. duration of symptoms (>6 weeks), iv. RF/ACPA+ve
Inflammatory 
arthritis
Persistent arthritis Sensitivity 0.71 Yes, e.g., Ref. 
(10, 46)Specificity 0.65 
(11)
Variables, target population, outcome assessed, and sensitivity and specificity of each model are described.
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cells (FDCs). Such organized ectopic lymphoid structures 
(ELS) within the target organ of an autoimmune disease are not 
restricted to RA and indeed are seen within the salivary glands of 
patients with Sjogren’s syndrome (47), the meninges of patients 
with multiple sclerosis (48) and in the thyroid of patients with 
autoimmune thyroid disease (49). Within rheumatoid synovial 
tissue, ELS can appear as tightly organized clusters closely resem-
bling SLOs, expressing high endothelial venules and CD21+ 
follicular dendritic cells (50) (Figure 1). Following these obser-
vations, much debate has focused on their pathophysiological 
significance. Indeed, a direct functional role in inflammation and 
autoantibody production for synovial ELS in RA pathogenesis 
has come from a number of studies including our own work using 
the Human RA SCID mouse model (51). We demonstrated that 
synovial graft ELS support the proliferation and differentiation 
of B cells as well as the expression of activation-induced cytidine 
deaminase, an enzyme critical for the processes of class switch 
recombination and affinity maturation of antibodies (52), which 
correlated with human ACPA titers (IgG) within mouse serum. In 
addition, grafts characterized by the presence of ELS (vs ELS−ve 
grafts) showed higher level of production of B cell growth factors, 
TNF alpha, and RANK-ligand, supporting a direct functional 
role for autoantibody and pro-inflammatory mediators produc-
tion by such structures. Of considerable importance, it should be 
noted that these events occurred in the absence of new immune 
cells infiltrating the grafts (SCID are immune deficient), indicat-
ing that ELS contribute to disease pathogenesis via protracted 
self-sustained immune activation. Further evidence includes the 
expression of RANK-ligand by activated T cells within synovial 
aggregates (53).
Direct evidence for a role in pathogenesis has also been sug-
gested from clinical studies: a significant association was reported 
in established RA between synovial aggregates and erosive burden 
(54), and in a prospective cohort of early arthritis, increased 
synovial B  cells were associated with the subsequent develop-
ment of RA (55). However, the same authors (56) and others in 
larger cross sectional cohorts have found no association between 
synovial aggregates and radiological damage (57) and a recent 
prospective study of early arthritis patients could not confirm 
either a diagnostic or prognostic role for aggregate synovial 
pathotypes (58). This has led a number of authors to conclude 
that lymphoid aggregates are a byproduct of inflammation, rather 
than a key component of the pathological process (59). However, 
interpretation of these data is complicated by a number of issues. 
First, no specific criteria are consistently used between studies 
to define aggregate synovial tissue histologically and as such the 
definition of ELS has been variously used to refer to aggregates of 
differing size and/or expressing different specific immunological 
cells (e.g., FDC, T  cells, B  cells). Further, comparing data from 
cross sectional studies including patients with varying (a) disease 
duration, (b) radiographic damage, and (c) treatment exposure 
(different therapeutic agents may influence synovial pathobiology 
differentially) has inherent methodological discrepancies. Finally, 
excessive prevalence of synovial tissue from the knee, as is the 
case with a number of studies, may introduce systematic bias, by 
including those patients with the most aggressive disease (60). 
These are crucial considerations, since a significant amount of data 
suggest that the induction of specific pathways related to lymphoid 
organization within the synovium (51, 53, 61, 62) may have short- 
and/or long-term effects on disease evolution. Thus, this concept 
requires further examination in a large-scale prospective study of 
early arthritis patients naïve to all therapy.
SYNOviAL PATHOTYPe AS A PReDiCTOR 
OF ReSPONSe TO THeRAPY
Clearly, given the relative ease of access, the identification of 
biomarkers within peripheral blood would be preferable to 
those from synovial tissue. However, the search for peripheral 
biomarkers for response to TNF inhibitors (TNFi) has so far 
been challenging (63–67), and overall, it can be concluded that at 
present the currently examined peripheral blood biomarkers lack 
either sufficient sensitivity or specificity for predicting response 
to TNFis. Notably, however, the type 1 interferon signature has 
been identified as a potential marker of resistance to rituximab 
therapy in RA (68), but this still requires further validation in 
independent cohorts. The search for synovial biomarkers has, 
therefore, been driven by the ongoing challenge of selecting the 
FiGURe 1 | ectopic lymphoneogenesis within the rheumatoid synovial 
membrane. The synovial inflammatory cell infiltrate has been demonstrated 
to organize into discrete organized clusters clearly visible following routine 
hematoxylin and eosin staining (A,B). The aggregate is primarily composed 
of T cells [CD3, (C,D)] and B cells [CD20, (e,F)] with a central follicular 
dendritic cell network [CD21, (G,H)]. Plasma cells [CD138, (i,J)] are shown 
surrounding the aggregate. Sequentially cut 3 µm sections of paraffin 
embedded rheumatoid arthritis (RA) synovial tissue from a patient with early 
RA are shown. Arrows indicate regions of positively stained cells. Left hand 
panel 4× magnification, right hand panel 20×, scale bar 200 µm.
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correct biologic in routine clinical practice, on the background of 
a burgeoning market for biologics usage in RA and by the limited 
utility so far demonstrated by peripheral blood biomarkers or 
clinical parameters.
TNF inhibitors are the most widely used biologic agents and 
have been in routine use for the longest and as such synovial patho-
biological changes are probably the most exhaustively studied. 
TNFα+/− LTα are inhibited by TNFi drugs, and both cytokines 
are key mediators of both the induction and maintenance of 
SLOs (69), so the capacity for modulation of synovial aggregates 
by TNFi has the potential to dissect the pathophysiology of the 
disease (Figure 2) as well as identification of biomarkers. Results 
from two groups have produced somewhat opposite results. An 
initial report from Cañete et al. (57) investigated the relationship 
between response to TNFi and the identification of large B cell 
aggregates with a pretreatment arthroscopic synovial biopsy in 
86 patients. Further, in a subgroup of 24 patients, the capacity 
of TNFi to modulate B cell aggregates and the relationship with 
clinical response was explored. The data suggested that synovial 
lymphoneogenesis was an independent negative predictor of 
response to therapy, and response to treatment was associated 
with regression of ELS. However, a subsequent report from 
Klaasen et al. (70) in which synovial biopsies were performed on 
97 patients prior to commencing treatment with infliximab iden-
tified the presence of lymphocyte aggregates as positive predictors 
of response at 16 weeks. There are a number of reasons for such 
discrepancies between the two groups including patient cohorts 
differing in terms of past TNFi exposure, disease duration, and 
variable follow-up times. In addition, a different definition of 
aggregate positive synovial tissue was used within each study, and 
the uniform use of a single TNFi was not consistent either within 
(57) or between the studies, a crucial consideration as increasing 
data suggest that efficacy of TNFis may involve more complex 
mechanisms than the simple division of drugs into either TNF 
antibody or TNF receptor (71). Interestingly, however, when the 
presence of synovial lymphocytic aggregates was added into a 
clinical prediction model (70) with TNF expression within the 
synovium, baseline DAS 28 score, and ACPA positivity, the power 
to predict response increased from 19 to 29%. A further potential 
synovial biomarker was identified when a preliminary study iden-
tified pretreatment levels of synovial TNF as a positive predictor of 
response to treatment (72) and a subsequent synovial-based study 
of 143 patients (73) supported these results with TNF expression 
within the synovial sublining explaining about 10% of the vari-
ance in response to therapy when multivariate linear regression 
was used to investigate synovial markers. Further, when a clinical 
prediction model incorporating both disease activity and TNF 
expression with the synovial sublining was formulated, 17% of 
variance in response to therapy could be explained (73). Thus, 
although at present, we remain some distance from personalized 
health care, these studies demonstrate proof of concept that in the 
long term the integration of synovial pathobiology into clinical 
prediction models may prove to be a useful clinical tool.
Whole tissue analysis using microarray technology has also 
been investigated to identify markers of response to therapy with 
such technology having the advantage of providing multiple simul-
taneous biomarkers. Its use was supported by two studies: the first 
where synovial tissue available from 10 patients pre- and post-TNF 
therapy (74) was examined and suggested a differential expression 
of genes between responders and non-responders and modulation 
of transcription profiling following treatment. The second study 
including 18 patients again suggested a differential expression 
of predominantly inflammatory genes in TNFi responders (75). 
Conversely, another group reported in a biopsy-based study of 
FiGURe 2 | Mechanisms of disruption of ectopic lymphoneogenesis within rheumatoid synovial tissue via currently licensed biologic agents for 
rheumatoid arthritis (RA). Disruption of ectopic lymphoneogenesis within the rheumatoid synovial membrane may be mediated by a number of biologic agents 
licensed for the treatment of RA and, therefore, has a putative role as a biomarker of response/resistance to biologic therapies. Rituximab induces death of CD20+ 
B cells via Ab or cell-mediated cytotoxicity, phagocytosis, or cell lysis. Abatacept, a CTLA-Ig fusion protein, prevents endogenous CTLA from binding to CD80/86 on 
B cells (functioning as antigen presenting cells) and so prevents co-stimulatory signals to the B cell. TNF inhibitors (TNFis) (inhibitors) such as infliximab bind to 
soluble and membrane-bound TNFα released by follicular dendritic cells (FDCs), and so inhibiting FDC-mediated B cell attraction. Tocilizumab inhibits binding of IL6 
to its receptor, preventing IL6-mediated B cell proliferation and differentiation.
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25 patients that a gene signature characterized predominantly by 
markers of cell division and immune activation predicted response 
to therapy (76). A large study of synovial tissue from 62 RA 
patients was established to attempt to identify further biomarkers 
of response using transcriptional analysis (77). This study did 
identify 38 genes associated with good response, but only within 
aggregate positive patients. Interestingly, more recently published 
data from Dennis et al. (78) have utilized whole tissue microarray 
as a tool to characterize the molecular profile of three previously 
reported (79) pathobiological synovial subgroups: myeloid, 
fibroid, and lymphoid subtypes. The same authors (78) also went 
on to identify two soluble serum markers associated with synovial 
pathotypes: ICAM1 (myeloid) and CXCL13 (lymphoid), and 
demonstrated that each was found to predict response to adali-
mumab (ICAM1) and tocilizumab (CXCL13). Such data require 
validation in larger prospective cohorts but highlight that disease 
heterogeneity may be more complex than that dissected by simple 
histopathological assessment of synovial tissue and, furthermore, 
suggest the potential role for synovial tissue in rationalizing choice 
of peripheral biomarkers. Therefore, it seems likely that any robust 
prediction model will have to incorporate multiple pathobiologi-
cal as well as clinical biomarkers.
Thus, at present, despite these observations, the capacity to 
predict response to TNFi remains remote to practicing clinicians. 
What seems crucial to stress, particularly with an ever-increasing 
number of TNFis available, each with unique pharmacological 
characteristics and capable of modulating unique pathobiologi-
cal processes, is that extrapolating biomarkers from individual 
TNFis to the whole group will likely prove a futile exercise. What 
is needed are large-scale pathobiological studies conducted in 
patients naïve to all biologic therapy and focusing on individual 
TNFis, this approach promises a unique opportunity to dissect 
disease mechanism in parallel with identifying novel biomarkers.
Rituximab, a monoclonal antibody against CD20, has 
demonstrated efficacy in RA, with response rates of around 60% 
(80). Although seropositivity for RF and/or ACPA has emerged as 
a positive predictor of response to treatment following a subgroup 
analysis of a number of studies (81–83), outcome to treatment 
remains unpredictable. Clinical studies pre and post rituximab 
therapy have demonstrated a number of potential pathways 
within synovial tissue that may explain the heterogenous clinical 
response seen despite apparent complete depletion in the periph-
eral blood. First, in a small study of 13 patients with synovial 
biopsies taken prior and at 8 weeks following standard rituximab 
treatment a trend toward clinical response and depletion of both 
synovial B cells and immunoglobulin synthesis was demonstrated 
(84). Second, a study of 24 patients identified reduction in the 
number of plasma cells, potentially originating locally within the 
synovial tissue, 16 weeks post therapy as a predictor of response to 
therapy (85). Finally, the identification of circulating pre plasma 
cells, by high sensitivity FACs analysis following the first cycle 
of rituximab associated with a poor response to treatment (86). 
Such cells are thought to originate from solid tissue, e.g., bone 
marrow, though the contribution of autoreactive clones escaping 
from the synovium may also play a role. It may well be concluded 
from these studies that modulating the functional B cell activity 
within synovial tissue has an important contribution on response 
to treatment, a hypothesis that is currently being explored by the 
authors of this paper through two randomized biopsy driven 
clinical trials (a) the National Institute for Health Research: 
Response, Relapse, Resistance to Rituximab (R4RA) study and 
(b) Stratification of Biologic Therapies for Rheumatoid Arthritis 
by Pathobiology (STRAP) study jointly funded by the Medical 
Research Council and Arthritis Research UK.
Early data on the synovial response to abatacept, a specific 
modulator of T-cell activation via inhibition of the CD80/86-CD28 
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interaction, have suggested a characteristic response in patients 
responding to treatment. In the study involving 16 RA patients 
with synovial tissue obtained prior and 16 weeks following the 
initiation of therapy, a significant downregulation of a number 
of pro inflammatory genes and a specific reduction in synovial 
CD20+ B cells was seen in patients responding to treatment (87). 
Further studies are awaited.
CONCLUSiON
A number of major advances in the management of RA have been 
made in the past decade. Importantly, overwhelming evidence 
now supports early intervention (1). The introduction of biologic 
drugs into the therapeutic armamentarium has been associated 
with a paradigm shift in treatment goals, from an often previously 
ill-defined response to therapy to disease remission or even cure. 
Such aims require early diagnosis and to target biologic treat-
ments appropriately, to patients with the worst prognosis and to 
those most likely to respond to individual agents. The currently 
available clinical prediction models are insufficiently sensitive or 
specific to allow reliable early diagnosis or indeed predict those 
with the worst prognosis and so far biomarkers for response to 
biologics are widely lacking. Although the simple pathological 
characterization of synovial tissue into subtypes seems unlikely 
to aid prognosis per se, an enormous number of questions remain 
before fully understanding how the heterogeneous synovial 
pathotypes integrate with disease pathogenesis and ultimately the 
heterogeneity of clinical phenotypes of disease. The complexity and 
diversity of RA pathogenesis is perhaps as such that would require 
more integrated and modular approaches as needed for cancer 
medicine (79, 88, 89). What is clear from the current conflicting 
data is that future synovial biopsy studies need to be conducted on 
large cohorts, including early arthritis patients naïve to DMARD 
therapeutic intervention. Significant progress in minimally inva-
sive ultrasound-guided techniques which are easily carried out by 
rheumatologists, safe and well tolerated by patients, and allow for 
the acquisition of synovial tissue both from small and large joint in 
most patients will facilitate the conduction of such studies. These 
may not only predict prognosis but have the potential to predict 
response to future therapeutic intervention at first presentation. It 
seems realistic to suggest that in future synovial pathobiology will 
be integrated into current clinical prediction models with positive 
benefits for patient care and health economics through accurate 
patient stratification.
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